Quintrio
Home

AGRICULTURAL CHEMICALS

Cibus, Inc. Class A Common Stock

CBUS

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Last trade $1.39
Day change +$0.19 (+15.83%)
Day range $1.19 – $1.52
Volume 618,814
Market cap $92M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$91.97M
Price / earnings
—
Price / book
-16.22×
Price / sales
20.29×
EV / sales
18.06×
EV / EBITDA
-1.77×

Profitability

Earnings per share
-$1.26
Return on assets
-32.04%
Return on equity
1,703.6%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.1×
Current ratio
0.95×
Quick ratio
0.95×
Cash ratio
0.77×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.78M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CBUS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$800K$994K$1.68M$1.06M$615K$933K$1.03M$1.21M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$800K$994K$1.68M$1.06M$615K$933K$1.03M$1.21M
Selling, general and administrative$5.39M$5.41M$5.08M$5.13M$5.27M$6.65M$9.86M$6.8M
Research and development$7.91M$8.51M$8.72M$9.39M$10.78M$12.23M$11.8M$12.43M
Total operating expenses$13.31M$13.92M$13.8M$23.63M$16.05M$18.88M$42.61M$19.24M
Operating income-$12.51M-$12.93M-$12.12M-$22.57M-$15.44M-$17.95M-$41.57M-$18.02M
Interest expense-$9.84M-$9.48M-$9.12M-$9.41M-$9.03M-$8.67M-$8.38M-$8.24M
Income before taxes-$21.94M-$22.14M-$21.22M-$31.94M-$24.31M-$26.53M-$49.39M-$25.8M
Income taxes$4K$6K$7K$6K-$6K$27K$2K$6K
Net income-$21.94M-$22.15M-$21.22M-$31.95M-$24.3M-$26.56M-$49.39M-$25.8M
Net income attributable to common shareholders-$21.94M-$22.15M-$21.22M-$31.29M-$23.54M-$25.37M-$46.89M-$23.1M
EBITDA-$11.41M-$11.76M-$10.92M-$12.17M-$14.02M-$16.37M-$18.99M-$16.38M
Basic earnings per share-$0.29-$0.29-$0.33-$0.59-$0.44-$0.61-$1.34-$0.87
Diluted earnings per share-$0.29-$0.29-$0.33-$0.59-$0.44-$0.61-$1.34-$0.87

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Cibus (CBUS) Reports Q3 Loss, Lags Revenue Estimates

Cibus reported a quarterly loss of $0.29 per share, missing consensus estimates of $0.27, with revenues of $0.8 million falling 41.61% short of expectations. The stock has declined 33.3% year-to-date versus the S&P 500's 11.3% gain. With a Zacks Rank #3 (Hold) rating and the Agriculture - Operations industry ranking in the bottom 7%, the company faces headwinds despite slight improvement in losses compared to the prior year.

Zacks Investment Research

Dole (DOLE) Q3 Earnings Miss Estimates

Dole reported quarterly earnings of $0.16 per share, missing consensus estimates of $0.31 by 48.39%, though revenues slightly exceeded expectations. The stock has underperformed the S&P 500 year-to-date. Cibus is expected to report results on November 12 with anticipated quarterly losses of $0.27 per share but significant revenue growth of 121% year-over-year.

GlobeNewswire Inc.

Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation

Cibus, Inc. (Nasdaq: CBUS) announced the appointment of Craig Wichner, founder of Farmland LP, as Chief Executive Officer, with Peter Beetham transitioning to President and Chief Operating Officer. The leadership change is part of the company's succession planning strategy as it focuses on commercializing its gene-editing technology for plant traits. Wichner brings experience in farmland investment management and regenerative agriculture practices.

GlobeNewswire Inc.

Cibus Announces Transfer of Gene-Edited Herbicide Tolerance Traits in Interoc Rice Seeds for Testing and Production

Cibus, Inc. has successfully transferred gene-edited herbicide tolerance traits in rice to its partner Interoc, marking a strategic milestone toward commercializing enhanced seed products in the Latin American market. The achievement demonstrates Cibus' ability to deliver traits on schedule using its Rapid Trait Development System, with expectations for additional gene-edited materials to be delivered to partners in the coming year as regulatory frameworks for gene editing continue to harmonize globally.

GlobeNewswire Inc.

Cibus Partnering with The John Innes Centre for UK Government’s Farming Innovation Programme Precision Breeding Initiative

Cibus, Inc. has been selected as a key technology partner in a UK Government-funded research project to develop oilseed rape varieties with resistance to Light Leaf Spot disease, which has caused estimated yield losses of £300 million. The LLS-ERASED project will utilize Cibus' proprietary Rapid Trait Development System to create durable, multi-disease resistant varieties, involving 12 industry and academic partners including the John Innes Centre and University of Hertfordshire.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 25, 20231-for-10reverse split
May 6, 20084-for-1forward split